Abstract. The cylindromatosis gene (CYLD) encodes a deubiquitinase that was initially identified as a tumor suppressor and has recently been investigated in connection with a variety of normal physiological processes. In contrast to its cell-proliferative activity, the effect of CYLD protein on cell migration has been a matter of debate. We investigated the effect of CYLD-siRNA on the migration activity of malignant melanoma cells. Expression of CYLD mRNA/protein was lower in 6 of 8 malignant melanoma cell lines than in 3 sets of primarycultured normal human epidermal melanocytes. Knockdown of CYLD significantly increased the proliferation activities of two melanoma cell lines (p<0.05), along with BCL3 nuclear translocation followed by CCND1 overexpression. In contrast to the proliferation-related activity, CYLD knockdown significantly decreased the cell migration of all the melanoma cell lines (n=7, p<0.05), and we demonstrated that the mechanism regulating melanoma cell migration was activation of RAC1 through the action of CYLD. Our findings provide new insight into the role of CYLD-induced RAC1 activation in melanoma cell migration.
Introduction
CYLD (cylindromatosis) was originally identified as a tumor suppressor gene that is mutated in familial cylindromatosis (Brooke-Spiegler syndrome), an autosomal-dominant predisposition to multiple tumors of skin appendages (1) . The CYLD gene encodes a deubiquitinating enzyme, which removes lysine 48-or lysine 63-linked polyubiquitin chains from target proteins (2) . Depending on the cellular context, CYLD has been shown to negatively regulate the NF-κB and/or JNK-signaling pathways resulting in suppression of cell proliferation and survival (3) (4) (5) (6) .
The mechanism by which CYLD exerts its tumor-suppressor function in vivo has been analyzed in CYLD-null mice, which are highly susceptible to chemically-induced skin tumors. This increased tumor incidence has been attributed to loss of an inhibitory interaction between CYLD and the proto-oncogene BCL3. The association of CYLD with BCL3, which results from activation and subsequent perinuclear translocation of the protein, leads to the removal of a lysine 63-linked ubiquitin chain from BCL3, which in turn inhibits the nuclear translocation and activity of BCL3 (7) . In the absence of CYLD gene expression, BCL3 is able to translocate into the nucleus where it forms a complex with the NF-κB p50 and p52 isoforms. This results in activation of the cyclin D1 (CCND1) promoter and increased proliferation and tumor growth (7) .
In contrast to the proliferation activity of tumor cells, the effect of CYLD protein in cell migration has been a matter of debate. Some CYLD mutants mimicking mutations that have been identified in human cylindromatosis contribute to the acquisition of metastatic potential by tumor cells (8) (9) (10) . However, Gao et al (11, 12) have demonstrated that CYLD downregulation causes a decrease of cell migration activity in both cancer and endothelial cells. The CYLD gene is known to contain 3 cytoskeleton-associated protein glycine-rich (CAP-Gly) domains, which exist in a number of microtubule-binding proteins and are responsible for their association with microtubules (MT). Knockdown of cellular CYLD expression dramatically delays MT regrowth after nocodazole washout, indicating a role for CYLD in promoting MT assembly (11) . Recently, direct association between CYLD and histone deacetylase-6 (HDAC6), a cytoplasmic histone deacetylase, has been documented (13) . The stability of MT is accompanied by post-translational modifications of α-tubulin (TUBA1) such as acetylation, which usually occurs after MT assembly (14) . The level of TUBA1 acetylation in cells is accurately adjusted by the activities of tubulin acetyltransferases and deacetylases, which catalyze the acetylation and deacetylation of TUBA1, respectively. ELP3 was identified very recently as TUBA1 acetyltransferase in neuronal cells (15) , while HDAC6 has been shown to deacetylate TUBA1 (16) . Even though HDAC6 contains both intrinsic nuclear import and export signals, it is found mainly in the cytoplasm (17) , where it localizes around the nucleus or at the leading edge of migrating (16) . Loss of HDAC6 function is involved in cell migration activity through several molecular mechanisms (18, 19) . HDAC6 is involved in multiple cellular processes, such as cell migration and adhesion, endocytosis, and stress responses. Overexpression of HDAC6 protein has been identified in a variety of cancer cells and mouse tumor models. The levels of HDAC6 expression in ovarian cancer cells and tissues were reportedly higher in low-grade and high-grade ovarian carcinomas than in benign lesions and immortalized ovarian surface epithelial cell lines (20) . HDAC6 expression was also upregulated in primary oral squamous cell lines and its level of expression was correlated with primary tumor stage (21) . Upregulation of HDAC6 in a variety of tumors and cell lines suggests an important role in cancer, and it is therefore being widely investigated.
We also recently demonstrated that the deacetylation system of nucleus accumbens-associated 1 (NACC1) and HDAC6 can modulate the status of both TUBA1 and cortactin (CTTN), which is an actin-crosslinking protein (22) . Motility of melanoma cells was affected via MT-and actin-dependent processes through the NACC1/HDAC6 deacetylation system. Moreover, overexpression of HDAC6 is a good prognostic and metastatic biomarker in human melanomas (22) . The aggressiveness of malignant melanoma is characterized by high metastatic ability and resistance to chemotherapy and immunotherapy (23) (24) (25) (26) . If CYLD negatively regulates HDAC6 function, it might act as a repressor of metastasis. In the present study, we examined the expression of the CYLD gene in malignant melanoma cell lines and primary cultures of normal human epidermal melanocytes (NHEMs), and investigated its association with tumor cell migration and proliferation activities. Antibodies. For immunofluorescence, polyclonal anti-CYLD antibody (Cell Signaling Technology, Danvers, MA, USA) and polyclonal anti-BCL3 (H-146) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used. 4'-6-diamino-2-phenylindole (DAPI) (Wako Pure Chemical Industries, Ltd., Osaka, Japan) solution was used to stain nuclei. The secondary antibody was Alexa Fluor ® 488 anti-rabbit IgG (Invitrogen). For immunoblotting of CYLD and BCL3, we used the same primary antibody as that used for immunofluoresence. The other primary antibodies were monoclonal CCND1 (cyclin D1) (Cell Signaling Technology), polyclonal LMNB1 (lamin B) (Santa Cruz Biotechnology), monoclonal TUBA1 (α-tubulin) (Sigma Chemical Co. Ltd., St. Louis, MO, USA), and monoclonal anti-GAPDH, Clone 1D4 (Covance, Princeton, NJ, USA).
Materials and methods

Cell
Western blotting. All cell lines were cultured to 70-80% confluence on 10-cm Petri dishes. Cold PBS (phosphate-buffered saline) was added, and the cells were removed from the dishes by scraping. After removal of the supernatants, the cell pellet was dissolved in cell lysis buffer [50 mM Tris-HCl, pH 8.0/150 mM NaCl/1 mM EDTA, pH 8.0/1% Triton X-100/0.1% sodium deoxycholate/0.1% SDS/1 mM PMSF/10 mM NaF/2 mM Na 3 VO 4 /1X complete protease inhibitor (Roche Diagnostics GmbH, Mannheim, Germany)]. Cell samples containing equal amounts of protein were mixed with 5X sample buffer, and heated for 5 min at 95˚C. Protein was electrophoresed on 4-12% Nu-PAGE for 45 min at 200 V constant voltage, and then transferred onto polyvinylidene difluoride membranes (Invitrogen) for 1 h at 30 V constant voltage. The membranes were blocked with 5% blocking reagent (Cell Signaling Technology) in 1X Tris-buffered saline/Tween-20 buffer for 1 h at room temperature, and immunostained with primary antibodies overnight at 4˚C. Then, the membranes were rinsed with Tris-buffered saline/ Tween-20 and incubated with horseradish HRP-conjugated secondary antibodies [anti-rabbit or -mouse IgG (GE Healthcare, Little Chalfont, UK)] for 1 h at room temperature. Signals were detected with ECL Prime (GE Healthcare) and ChemiDoc XRS (Bio-Rad Laboratories, Hercules, CA, USA). The intensity of the detected signals was measured using 1-D analysis software (Quantity One, Bio-Rad). For normalization of the target, GAPDH, LMNB1 or TUBA1 was used as an internal control.
Separation of nuclear and cytoplasmic fractions. Nuclear and cytoplasmic extracts from cells were prepared using a NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Thermo Scientific, Rockford, IL, USA), in accordance with the manufacturer's protocol. Briefly, the cells were pelleted by centrifugation at 500 x g for 3 min and the supernatants discarded. To obtain cytoplasmic extracts, ice-cold CERI (Thermo Scientific) buffer was added to the pellets. After vortexing and 10 min of incubation on ice, ice-cold CERII (Thermo Scientific) buffer was added for further incubation. Further centrifugation was conducted for 5 min, and the supernatants (cytoplasmic extracts) were immediately transferred to new tubes and placed on ice. The insoluble pellets were suspended in ice-cold NER buffer (Thermo Scientific). After vortexing and incubating on ice, the tubes were centrifuged at 16,000 x g for 10 min. The supernatants (nuclear fractions) were immediately transferred to clean, prechilled tubes. Extracts were stored at -80˚C until Western blotting experiments.
RNA isolation and quantitative reverse transcriptase PCR.
Total RNA was extracted with TRIzol reagent (Invitrogen), and transcribed to cDNA using a SuperScript III First-Strand Synthesis System (Invitrogen). For quantitative evaluation of the relevant mRNAs, we used Custom TaqMan Gene Expression Assays (CYLD, Hs00211000_m1; CCND1, Hs00765553_ml; Invitrogen), and an ABI PRISM 7500 instrument (Invitrogen). For normalization of the target, glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Invitrogen) was used as an internal control. All reactions (each containing 3 templates) were run in triplicate, and average fold differences were calculated by normalizing the relative expression (∆∆Ct values) according to ABI User Bulletin no. 2.
siRNA knockdown of the CYLD gene. For silencing of CYLD gene mRNA, 3 predesigned CYLD-specific siRNA sequences (no. 1, s590; no. 2, s591; no. 3, s592; Silencer Select Predesigned siRNA, Invitrogen), and control non-specific human siRNAs (Silencer Select Predesigned siRNA Negative Control no. 1, 4390843; no. 2, 4390844, Invitrogen) were used. siRNA transfection was performed using Lipofectamine RNAiMAX Reagent (Invitrogen) according to the manufacturer's instructions.
Confocal microscopy. Cells were washed with PBS and fixed with 4.0% formaldehyde and 0.5% Triton X-100 for 20 min. The slides were then blocked with 5% bovine serum albumin for 30 min at room temperature. After 3 washes with PBS, the slides were incubated with a primary antibody in blocking buffer at 4˚C. The slides were incubated with a secondary antibody for 3 h at 37˚C. Cells were counterstained with DAPI and imaged with a Nikon EZ-C1 confocal microscope (Nikon Co., Tokyo, Japan).
RAC1 activity assay. An Active Rac1 Pull-Down and Detection Kit was purchased from Thermo Scientific and experiments were performed in accordance with the manufacturer's protocol. Lysed samples in RIPA buffer were incubated with 20 ml of glutathione S-transferase-human Pak1-p21-binding domain for 1 h at 4˚C, followed by 3 times with wash buffer. Proteins bound to agarose beads were eluted in 50 ml of 2X SDS sample buffer and subjected to Western blot analysis.
Tumor cell migration assay. Confluent cell monolayers were scratched to create a wound, and then 0, 24 and 48 h later, 3 different fields of each wound were photographed with a phase-contrast microscope. Three independent experiments were performed. Measurements of the width of each wound were performed under each experimental condition. At the start of the experiment, the wound size was measured and scored as 100%. After 24 and 48 h, the width of the residual wound was measured and the average percentage of wound closure was calculated by using the free web software package Image J (http://rsb.info.nih. gov/ij).
Cell proliferation assay. Cell proliferation assays were performed using a Cell Counting Kit-8 (Dojindo Co., Kumamoto, Japan). Cells were plated in 96-well plates at 1x10 4 Statistical analysis. All data are presented as means ± standard error. Correlations between CYLD protein expression and clinicopathological data were analyzed by Fisher's exact test. To correlate the results of CYLD expression with overall survival in patients with malignant melanomas, Kaplan-Meier survival analysis and log-rank test were performed. Mann-Whitney U test for non-parametric samples was used for biological experimental data analyses. The level of significance was considered to be p<0.05.
Results
Expression of the CYLD gene in cell lines and primary tumors of malignant melanomas.
We first examined mRNA/protein expression of CYLD in 8 melanoma cell lines and 3 primary cultures of NHEMs (Fig. 1) . Under the recommended condi- tions and at 60-70% confluency, expression of CYLD protein decreased in 6 (75%) of the 8 melanoma cell lines in comparison with 3 NHEMs (Fig. 1) . Two melanoma cell lines (MM-RU and PM-WK) expressed CYLD protein at levels similar to those in the 3 NHEMs (Fig. 1A-C) . Expression of CYLD mRNA was consistent with that of the protein (Fig. 1D) .
Next, we evaluated CYLD protein expression in 49 patients with malignant melanomas and in 10 with non-neoplastic skin disease. Dense immunoreactivity for CYLD protein was observed in both skin keratinocytes and epidermal melanocytes ( Fig. 2A) . Immunoreactivity for CYLD protein was negative in 40 (82%) of 49 primary melanomas (Fig. 2B) , and the remaining 9 (18%) exhibited a weak reaction (Fig. 2C) . Although we investigated the relationships between CYLD immunoreactivity and clinicopathological data for the 49 melanoma patients and their disease outcome, no significant relationship was evident.
Cell migration activity induced by treatment with CYLD-siRNA in melanoma cell lines. We first evaluated the knockdown efficiency of CYLD-siRNAs (nos. 1, 2 and 3; 10 nM) in a malignant melanoma cell line (PM-WK, Fig. 3 ). In comparison with negative control siRNA, all the siRNAs caused 80-90% downregulation of both CYLD mRNA and protein expression (Fig. 3) . Using no. 1 CYLD siRNA, we then examined phenotypic changes in the migration activities of the 7 melanoma cell lines (except for HMV-I, as its growth pattern was unsuitable for the scratch assay). CYLD knockdown significantly decreased the migration activity of all 7 melanoma cell lines in comparison with the negative control at 24 and 48 h (p<0.05, Mann-Whitney U test; Fig. 4) .
Effects of treatment with CYLD-siRNA on microtubule acetylation in melanoma cell lines.
We evaluated MT after CYLD knockdown by siRNA treatment in two CYLD-overexpressing melanoma cell lines (MM-RU and PM-WK). Accumulation of acetylated tubulin around the nucleus was decreased in comparison with control siRNA treatment in both cell lines (Fig. 5A) , whereas no marked change of total TUBA1 distribution was found throughout the cytoplasm. Immunoblot analyses showed that CYLD knockdown induced a decrease of acetylated tubulin in comparison with control siRNA (Fig. 5B) . Knockdown of CYLD gene induced the activation of HDAC6 deacetylation, and might introduce dynamic state of MT.
Activation of RAC1 by treatment with CYLD-siRNA in melanoma cell lines. A contradiction was found between MT acetylation status and migration activity in two melanoma cell lines treated with CYLD-siRNA. Next, we tested RAC1 activation in these cells, because it has recently been clarified that silencing of CYLD is involved in MT dynamics and represses the migration activity of endothelial cells, suggesting that repression of active RAC1 contributes to a decrease of endothelial cell migration (12) . We also confirmed a marked decrease of active RAC1 expression (p<0.05) in both melanoma cell lines (Fig. 6 ), in accord with the results of Gao et al (12) .
Effects of treatment with CYLD-siRNA on proliferation activity of melanoma cell lines. Treatment with CYLD-siRNA decreased the proliferation of two CYLD-overexpressing melanoma cell lines (Fig. 7A) . We also identified BCL3 translocation to the nucleus by confocal microscopy (Fig. 7B) and Western blot analyses using nuclear and cytoplasmic extracts (Fig. 7C) , as described previously (7). This in turn induced overexpression of CCND1 mRNA/protein (Fig. 8) .
Discussion
At the start of this study, we had hypothesized that knockdown of the CYLD gene might accelerate the motility of melanoma cells, because CYLD inhibits HDAC6 deacetylation activity (13). We recently reported that disruption of HDAC6 was closely associated with a decease of in vitro migration and invasion activities of melanoma cells (22) . Inactivation of HDAC6 induced hyperacetylation of not only TUBA1 (13) but also CTTN (22) . It introduced stabilization of MT dynamicity, and prevented the translocation of cortactin protein to the cell periphery, thus blocking its association with F-actin, and impairing the motility of melanoma cells. Moreover, CYLD downregulation is associated with aggressive tumor behavior in the development of human cancers including not only malignant melanoma but also tumors of the colon, lung and kidney, and also cervical and hepatocellular carcinomas (10, 27) . Considering these in vitro and in vivo findings as a whole, our hypothesis pertaining to the relationship between CYLD and the motility of melanoma cells would appear to be reasonable. However, our experiments yielded findings that were contradictory to this concept.
Massoumi and colleagues (10) demonstrated that mitogenic and metastatic properties of melanoma cells were promoted by downregulation of CYLD through the action of Snail1, whose expression is induced by BRAF-mediated activation of extracellular signal-regulated kinase (ERK). Snail1-dependent inhibition of CYLD transcription results in stimulation of cyclin D1 and N-cadherin expression in melanoma cells, leading to enhanced proliferation, migration, and invasiveness of melanoma cells in vitro, as well as tumor growth and metastasis in vivo (10) . In addition, tumors developing in CYLD-truncated mutant mice were reportedly prone to malignant progression and lymph node metastasis along with activation of c-Jun-NH2-kinase (JNK) and the downstream c-Jun and c-Fos proteins (8) . Moreover, topical application of a pharmacologic JNK inhibitor significantly reduced tumor development and abolished metastasis in the transgenic mice (8) .
Some reports have suggested that CYLD inactivation confers migration activity on tumor cells, contrary to the results obtained by Gao et al (11, 12) . This discrepancy could be attributable to the method used for inactivation of CYLD functions. Massoumi et al (2,10) and de Marval et al (8) used a murine model of patient-relevant mutations observed in familial cylindromatosis, these transgenic mice lacked the catalytic domain of the CYLD C-terminus and required TPA stimulation for development of skin tumors. In contrast to these studies, Gao et al employed simple CYLD knockdown by siRNA treatment, which repressed the cell migration activities of HeLa and endothelial cells, in accord with our results obtained using melanoma cell lines (11, 12) . CYLD protein binds to both HDAC6 and TUBA1 through its N-terminal CAP-Gly domains, and increases the level of acetylated tubulin (13) . The truncated C-terminus of CYLD protein might exert a dominant negative effect on deubiquitinase activity for the To ensure equal protein loading in the nuclear and cytosolic fractions, anti-LMNB1 and anti-TUBA1 antibodies were used. nuclear translocation of BCL3 and acquisition of cell proliferation. However, this would repress HDAC6 deacetylation activity, resulting in induction of MT hyperacetylation and stabilization of tumor cell motility. In fact, keratinocytes derived from Cyld null mice or melanoma cells treated with siRNA (presented in this study) showed activation of HDAC6 deacetylation activity and a decreased level of acetylated tubulin. However, the migration activity of these cells was markedly repressed. Taken together, these findings suggest that another molecular mechanism should be considered for the decrease of cell migration caused by knockdown of the CYLD gene.
Gao et al demonstrated that silencing of CYLD introduced RAC1 activation as an important factor contributing to the action of CYLD in regulating endothelial cell migration and angiogenesis (12) , in accord with our results for melanoma cells. It is still unclear how CYLD is involved in RAC1 activation, and contributes to the effects of cell migration. One feasible idea is that CYLD may deubiquitinate RAC1 and thereby promote RAC1 activation to enable efficient cell migration. This notion is supported by observations that RAC1 activity is regulated by ubiquitination (28, 29) . As CYLD is involved in melanoma cell migration, further studies of post-transcriptional regulation of MT and/or RAC1 could provide new targets for future therapeutic intervention to control melanoma cell motility. 
